Paul D. Nathan
Northwood, ENG, United Kingdom
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 56 publications
Five-year survival with tebentafusp in metastatic uveal melanoma.
Journal: Annals of oncology : official journal of the European Society for Medical Oncology
Published: March 02, 2026
Uveal melanoma: ESMO-EURACAN Clinical Practice Guideline for diagnosis, treatment and follow-up.
Journal: ESMO open
Published: September 24, 2025
Gastrointestinal Dysautonomia After Immune Checkpoint Inhibitor Therapy: A Case Series and Systematic Review.
Journal: Neurogastroenterology and motility
Published: August 01, 2025
Efficacy of adjuvant therapy in patients with stage IIIA cutaneous melanoma.
Journal: Annals of oncology : official journal of the European Society for Medical Oncology
Published: November 26, 2024
Cutaneous melanoma: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up.
Journal: Annals of oncology : official journal of the European Society for Medical Oncology
Published: August 15, 2024
Immune biomarker evaluation of sequential tyrosine kinase inhibitor and nivolumab monotherapies in renal cell carcinoma: the phase I TRIBE trial.
Journal: Immuno-oncology technology
Published: May 02, 2024
Overall survival from tebentafusp versus nivolumab plus ipilimumab in first-line metastatic uveal melanoma: a propensity score-weighted analysis.
Journal: Annals of oncology : official journal of the European Society for Medical Oncology
Published: August 11, 2023
Immuno-oncology approaches in uveal melanoma: tebentafusp and beyond.
Journal: Immuno-oncology technology
Published: July 24, 2023
Adjuvant Nivolumab versus Ipilimumab in Resected Stage III/IV Melanoma: 5-Year Efficacy and Biomarker Results from CheckMate 238.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: November 07, 2022
Tebentafusp: a first-in-class treatment for metastatic uveal melanoma.
Journal: Therapeutic advances in medical oncology
Published: August 26, 2022
Spartalizumab or placebo in combination with dabrafenib and trametinib in patients with BRAF V600-mutant melanoma: exploratory biomarker analyses from a randomized phase 3 trial (COMBI-i).
Journal: Journal for immunotherapy of cancer
Published: May 23, 2022
Last Updated: 09/26/2026